Ondansetron for the Management of Atrial Fibrillation

NCT ID: NCT05844501

Last Updated: 2025-05-28

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-22
• Study Completion Date: 2027-12-31

Brief Summary

"Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart called a potassium current. There is a newer potassium current called IKas that can contribute to Afib. A medicine called ondansetron is used to keep people with cancer from getting sick to their stomach and throwing up. The investigators have found that ondansetron blocks IKas, and the investigators think that this means that ondansetron may work well to treat Afib. So, in this study the investigators want to find out if ondansetron can: 1) Reduce the amount of time that people have Afib, and 2) Slow down the heart rate when people have Afib. The investigators will study 80 people who are scheduled to have an AF ablation. Several weeks prior to undergoing the ablation procedure, these AF patients will be assigned by chance (like flipping a coin) to one of two groups: ondansetron 8 mg by mouth twice daily or a sugar pill (placebo), which they will take for 28 days. The people in the study will not know whether they are receiving ondansetron or placebo. The investigators will find out if ondansetron reduces the percentage of time that people are in Afib. Also, the investigators will find out if ondansetron slows the heart rate while people are having Afib. The investigators will compare the people in the study who take ondansetron with the people in the study who take placebo. This research will help the investigators to find out if ondansetron can be used as a medicine for people who have Afib.

Detailed Description

Atrial fibrillation (AF) is a common arrhythmia associated with symptoms, stroke, systemic embolism, heart failure, dementia, and mortality. Guideline-recommended strategies for conversion to and maintenance of sinus rhythm (SR) and ventricular rate (VR) control are of limited efficacy and/or are poorly tolerated. There is a critical need for safer, more effective alternatives for AF drug therapy. The apamin-sensitive small-conductance calcium-activated potassium (SK) ion current (IKas) is important for repolarization in the atria and pulmonary vein muscle sleeves. IKas also contributes to sinoatrial and AV node electrophysiology. Therefore, IKas may be a target for rhythm and rate control in AF. Evidence suggests: 1) IKas plays an important role in the mechanism of AF, 2) The antiemetic agent ondansetron at therapeutic concentrations is a potent IKas inhibitor, and 3) Ondansetron is a cardiac-selective IKas inhibitor. Thus, the investigators hypothesize that ondansetron is effective for rhythm and rate control in patients with AF. Specific Aim 1: Determine the efficacy and safety of ondansetron for reducing AF burden. This aim will be achieved via a prospective, randomized, double-blind placebo-controlled study in patients with AF (n=80). Patients with AF scheduled to undergo an elective catheter AF ablation (pulmonary vein isolation) will be randomized in double-blind fashion to receive ondansetron 8 mg twice daily (n=40) or matching placebo (n=40) for 28 days. The study drug/placebo will be initiated several weeks prior to the ablation procedure, and the 28 days of treatment will be complete at least 3 days prior to the ablation. Continuous ECG recording will be performed using 2 consecutive adhesive skin patch ECG monitors, which provide 14-days of continuous recording. The primary outcome measure will be AF burden (percentage of time in AF). Specific Aim 2: Determine the efficacy and safety of ondansetron for VR control in AF. The effect of ondansetron versus placebo on VR control will be assessed. Primary outcome measures will be mean daily heart rates in AF on days 7, 14, 21 and 28 days following initiation of ondansetron/placebo.

Conditions

Atrial Fibrillation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Ondansetron

Patients with atrial fibrillation scheduled to undergo AF ablation will receive treatment with ondansetron 8 mg orally twice daily for 28 days (n=40)

Group Type: EXPERIMENTAL

Ondansetron 8mg

Intervention Type: DRUG

Ondansetron 8 mg orally twice daily for 28 days

Placebo

Patients with atrial fibrillation scheduled to undergo AF ablation will receive treatment with matching placebo orally twice daily for 28 days (n=40)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matched placebo orally twice daily for 28 days

Interventions

Ondansetron 8mg

Ondansetron 8 mg orally twice daily for 28 days

Intervention Type: DRUG

Placebo

Matched placebo orally twice daily for 28 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Men and women 18-100 years of age
• ECG-verified AF and/or atrial flutter requiring elective catheter ablation
• Receiving guideline-recommended anticoagulation (if CHA2DS2-VASc score is 0 (men) or 1 (women), anticoagulation can be omitted)

Exclusion Criteria

• Women of childbearing potential
• Subject reported syncope of unknown origin within the previous 6 months
• Diagnosis of active thyrotoxicosis
• Diagnosis AF from reversible noncardiac causes
• Diagnosis of acutely decompensated heart failure
• Left ventricular ejection fraction less than or equal to 20%

• New York Heart Association class IV heart failure
• Diagnosis of severe liver disease (Child-Pugh score greater than or equal to 10)
• Cardiac surgery (preceding 2 months)
• Not receiving anticoagulation due to contraindications (as determined by treating physician and recorded in the medical record)
• Pretreatment QRS > 180 ms, QTc > 450 ms within two weeks of screening visit
• Heart rate < 50 beats per minute in SR
• Diagnosis of hypotension
• Diagnosis of Wolff-Parkinson-White syndrome
• Previous ondansetron hypersensitivity or serotonin syndrome
• Diagnosis of phenylketonuria
• Diagnosis of congenital long QT syndrome
• Concomitant therapy with both beta-blockers and a nondihydropyridine CCB
• History of drug-induced torsades de pointes or QTc prolongation
• Concomitant therapy with QTc-prolonging medications (www.crediblemeds.org), except amiodarone and propafenone
• Concomitant therapy with serotonergic drugs (selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, mirtazapine, lithium, tramadol), apomorphine, phenytoin, carbamazepine, oxcarbazepine, rifampin.
• Left ventricular ejection fraction < 20% and those with NYHA class IV heart failure with reduced ejection fraction (confirmed by diagnosis or echocardiogram within 6 months of enrollment in screening)
• Patients with pre-existing allergies to adhesives
• Patients with neuromuscular stimulators

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

American Heart Association

OTHER

Sponsor Role: collaborator

Purdue University

OTHER

Sponsor Role: collaborator

Indiana University

OTHER

Sponsor Role: lead

Responsible Party

James E. Tisdale

Adjunct Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

James E Tisdale, PharmD

Role: PRINCIPAL_INVESTIGATOR

Purdue University

Locations

Indiana Clinical Research Center

Indianapolis, Indiana, United States

Site Status: RECRUITING

Indiana University Health Methodist Hospital

Indianapolis, Indiana, United States

Site Status: NOT_YET_RECRUITING

Purdue University

Indianapolis, Indiana, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

James E Tisdale, PharmD

Role: CONTACT

jtisdale@purdue.edu

317-880-5418

Tanner Sergesketter, BSN

Role: CONTACT

thom1277@purdue.edu

Facility Contacts

Scott Denne, MD

Role: primary

sdenne@iupui.edu

317-274-4920

Sharon Cromer

Role: backup

scromer2@iupui.edu

317-278-3446

Richard J Kovacs, MD

Role: primary

rikovacs@iu.edu

317-274-0907

James E Tisdale, BSc, PharmD

Role: primary

jtisdale@purdue.edu

317-880-5418

Heather Jaynes, MSN

Role: backup

hwroblew@iu.edu

317-847-2094

Other Identifiers

22TPA964193

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

16581

Identifier Type: -

Identifier Source: org_study_id